Melacine

Melacine

An allogeneic melanoma tumour cell lysate combined with the adjuvant Detox, which was used as an anti-tumour vaccine and had some (minimal) benefit for advanced and metastatic melanoma, and in melanoma patients who expressed HLA-I A2 and/or HLA-C3.
References in periodicals archive ?
Introduction to Skin Cancer Vaccine - Global Skin Cancer Vaccine Market Analysis - Global Skin Cancer Vaccine Pipeline by Company & Phase - Global Skin Cancer Vaccine Pipeline: 47 Vaccines - Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines - Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline) - Personalized Cancer Vaccines: Progress & Possibilities - Skin Cancer Vaccine Mechanism
The manufacturer of the Melacine melanoma vaccine is planning to finalize plans for a second pivotal trial of the vaccine in people with stage II disease.
Mitchell MS, Von Eschen KB: Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma (Abstract).
On February 15, Corixa and Schering Canada, a wholly owned subsidiary of Schering-Plough Corporation, announced the immediate availability in Canada of Corixa's Melacine vaccine, a therapeutic vaccine for treatment of Stage IV melanoma.
Corixa Corporation (Nasdaq:CRXA), a research and development-based biotechnology company, has released additional data from its Phase III, randomized trial to evaluate Corixa's therapeutic vaccine Melacine, for the treatment of Stage II melanoma.
Melacine is currently in the Food and Drug Administration approval process.
ABX MA1, Alfanative , ALLOVECTIN-7, AP 12009, Avastin, BAY 504798, Canvaxin, Carboplatin, Carmustine, Ceplene Maxamine, Cisplatin, CP 4055, Dacarbazine, Dexosome, Didemnin B, Ecromeximab, Elea Vaccine, EMD 273063, Enhanzyn, F 50040, Genasense, GMK, GV 1001, GVAX, Iboctadekin, ILX 651, INGN 241, INO 1001, Intron A, Kahalalide F, Karenitecin, KOS 953, Lenalidomide, Lomeguatrib, MDX-010, Melacine, Melphalan, MJV 101, M-VAX, NOVOVAC-M1, NY-ESO-1 ISCOMS, Oncophage, OncoVax, OncoVEXGM-CSF, Paclitaxel, PD 0325901, Peginterferon alfa-2b, Pivanex, Proleukin , ProMune, QS-21, SB 249553, SB 715992, Sorafenib, Talabostat, Tamoxifen, Temozolomide, Temozolomide, Uvidem, Vinblastine/Vinorelbine, Virulizin, Vitaxin, Zadaxin
DCVax), Gastrimmune, GMK, LymphoCide, Melacine, M-Vax, MyVax, Oncophage, OncoVAX, Osidem, Ovarex, Provenge, Theratope, TriGem, TroVax and many more.
Jacobs served as Senior Vice President of Clinical Development and Chief Medical Officer at Corixa, now a subsidiary of GlaxoSmithKline, where she oversaw a team that obtained Canadian approval for Melacine, a cancer vaccine for melanoma, and two U.
Progress analysis on cancer vaccine candidates: Progress Profile Allovoctin-7 Progress Profile Avicine Progress Profile BEC2 Progress Profile Canvaxin Progress Profile CeaVac Progress Profile DCVax Progress Profile Gastrimmune Progress Profile GMK Progress Profile Lymphocide Progress Profile Melacine Progress Profile M-Vax Progress Profile MyVax Progress Profile Oncophage Progress Profile OncoVax Progress Profile Osidem Progress Profile Ovarex Progress Profile Provenge Progress Profile Theratope Progress Profile TroVax
Corixa's cell therapy Melacine is based on the "cell vaccine" concept and consists of lysed (broken) cells from two human melanoma cell lines combined with Detox adjuvant.
Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and.